within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD19_LinagliptinAndEmpagliflozin;

model LinagliptinAndEmpagliflozin
  extends Pharmacolibrary.Drugs.ATC.A.A10BD19;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD19</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Linagliptin and empagliflozin is a fixed-dose combination of two oral antidiabetic agents: linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor. The combination is approved for the treatment of type 2 diabetes mellitus to improve glycemic control in adults.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults based on separate data for linagliptin and empagliflozin. No existing publication reports full combined fixed-dose PK parameters as of knowledge cutoff.</p><h4>References</h4><ol><li><p>Friedrich, C, et al., &amp; Woerle, HJ (2013). A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. <i>Clinical therapeutics</i> 35(1) A33–A42. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2012.12.002&quot;>10.1016/j.clinthera.2012.12.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23328275/&quot;>https://pubmed.ncbi.nlm.nih.gov/23328275</a></p></li><li><p>Hammad, RW, et al., &amp; Latif, R (2024). Cubosomal functionalized block copolymer platform for dual delivery of linagliptin and empagliflozin: Recent advances in synergistic strategies for maximizing control of high-risk type II diabetes. <i>Drug delivery and translational research</i> 14(3) 678–695. DOI:<a href=&quot;https://doi.org/10.1007/s13346-023-01423-7&quot;>10.1007/s13346-023-01423-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37805954/&quot;>https://pubmed.ncbi.nlm.nih.gov/37805954</a></p></li><li><p>Glund, S, et al., &amp; Friedrich, C (2017). Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet . <i>International journal of clinical pharmacology and therapeutics</i> 55(4) 355–367. DOI:<a href=&quot;https://doi.org/10.5414/CP202929&quot;>10.5414/CP202929</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28290274/&quot;>https://pubmed.ncbi.nlm.nih.gov/28290274</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end LinagliptinAndEmpagliflozin;
